Lake.com and Interhome Announce Strategic Partnership to Expand European Lakeside & Waterfront Vacation Rentals

30.10.2025 07:00:00 CET | Business Wire | Press Release

Lake.com, the vacation-rental marketplace built for life by the water, partnered with Interhome, one of Europe’s most established managers of holiday homes and apartments. The collaboration brings Interhome’s quality-checked villas, chalets, and apartments across 20+ European countries to Lake.com travelers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029035564/en/

Lake.com and Interhome announce partnership with 40,000 new vacation rentals.

Today, Interhome’s professionally managed inventory becomes bookable on Lake.com, combining real-time rates and availability with Interhome’s local service offices for key handover, cleaning, and guest support. This marks Lake.com’s European expansion, deepening selection in high-demand lakeside and coastal destinations.

Lake.com’s integration with Interhome adds more than 40,000 holiday homes—from Italy’s Lake Garda and Como to Austria’s Salzkammergut, Switzerland’s Lakes Lucerne and Geneva, Germany’s Lake Constance, and France’s Lake Annecy, plus Mediterranean and Adriatic coasts.

Why It Matters

Trusted supply: Interhome’s standardized quality checks and local service provide families with reliable, self-catering stays.
Waterfront depth: Expanded coverage on lakes and coastlines in Italy, France, Spain, Croatia, Switzerland, Austria, Germany, Portugal, and the Netherlands.
Family-friendly: Villas with pools, alpine chalets, and family-sized apartments with full kitchens, outdoor space, and pet-friendly options.

“Families want the right home on the right lake, without the friction,” said David Ciccarelli, Founder & CEO of Lake.com. “Partnering with Interhome brings quality‑checked, locally serviced homes into a water‑first experience, from the Alps to the Adriatic. It’s a major step in our European expansion and a win for travelers who value space, kitchens, and trusted standards.”

“Interhome is delighted to partner with Lake.com to showcase our villas, chalets, and apartments to travelers seeking lakeside and coastal stays,” said Michael Figlestahler, Chief Sales Officer at Interhome. “Our local service offices, consistent quality checks, and decades of experience complement Lake.com’s curated, water‑centric marketplace—helping families and groups book with confidence.”

About Lake.com

Lake was founded by a husband-and-wife team passionate about helping families experience the beauty of God’s creation. The platform offers 40,000+ vacation homes by the water across North America and Europe. Visit https://www.lake.com

About Interhome

Founded in 1965 near Zurich, Interhome manages 40,000+ quality-checked properties across 20+ European countries, combining standardized quality controls with local offices for key handover, cleaning, and guest support. Learn more at https://www.interhome.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20251029035564/en/

Contacts

Media:

Stephanie Ciccarelli
Lake Inc.
Chief Marketing Officer
(226) 794-5744
media@lake.com

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom